INTRODUCTION: The one-step nucleic acid amplification (OSNA) is a molecular procedure that yields a semiquantitative result for detection of nodal metastasis. Size of metastasis in the sentinel lymph node (SLN) by conventional histology has been described as a predictive factor for additional axillary metastasis. The objective of this study is to quantify intraoperatively the total tumoral load (TTL) in the positive SLNs assessed by OSNA and to determine whether this TTL predicts non-SLN metastasis in patients with clinically node negative early stage breast cancer. METHODS: 306 patients with cT1-3N0 invasive breast cancer who had undergone intraoperative SLN evaluation by OSNA were included. TTL was defined as the addition of CK19 mRNA copies of each positive SLN (copies/μL). RESULTS: TTL was a predictive factor of additional non-SLN metastasis in the complete axillary lymph node dissection (cALND) (OR, 1.67; 95% CI, 1.18-2.35). In the multivariate analysis, the TTL was a predictor of non-SLN metastasis in HR positive patients (OR, 1.69; 95% CI, 1.19-2.41). In our cohort of patients, with a TTL ≤1.2 × 10(5) copies/μL, there was a specificity of 85.3% and negative predictive value (NPV) of 80%. If we consider only the HR positive patients, with a TTL ≤5 × 10(5) copies/μL there was a specificity of 86.7% and NPV of 83.7%. CONCLUSIONS: TTL assessed by OSNA assay predicts for additional non-SLN metastasis and this intraoperative tool can help guiding decisions on performing a cALND in breast cancer patients.
INTRODUCTION: The one-step nucleic acid amplification (OSNA) is a molecular procedure that yields a semiquantitative result for detection of nodal metastasis. Size of metastasis in the sentinel lymph node (SLN) by conventional histology has been described as a predictive factor for additional axillary metastasis. The objective of this study is to quantify intraoperatively the total tumoral load (TTL) in the positive SLNs assessed by OSNA and to determine whether this TTL predicts non-SLN metastasis in patients with clinically node negative early stage breast cancer. METHODS: 306 patients with cT1-3N0 invasive breast cancer who had undergone intraoperative SLN evaluation by OSNA were included. TTL was defined as the addition of CK19 mRNA copies of each positive SLN (copies/μL). RESULTS: TTL was a predictive factor of additional non-SLN metastasis in the complete axillary lymph node dissection (cALND) (OR, 1.67; 95% CI, 1.18-2.35). In the multivariate analysis, the TTL was a predictor of non-SLN metastasis in HR positive patients (OR, 1.69; 95% CI, 1.19-2.41). In our cohort of patients, with a TTL ≤1.2 × 10(5) copies/μL, there was a specificity of 85.3% and negative predictive value (NPV) of 80%. If we consider only the HR positive patients, with a TTL ≤5 × 10(5) copies/μL there was a specificity of 86.7% and NPV of 83.7%. CONCLUSIONS: TTL assessed by OSNA assay predicts for additional non-SLN metastasis and this intraoperative tool can help guiding decisions on performing a cALND in breast cancerpatients.
Authors: Thorsten Heilmann; Micaela Mathiak; Jakob Hofmann; Christoph Mundhenke; Marion van Mackelenbergh; Ibrahim Alkatout; Antonia Wenners; Christel Eckmann-Scholz; Christian Schem Journal: J Cancer Res Clin Oncol Date: 2013-08-02 Impact factor: 4.553
Authors: Francesca Combi; Alessia Andreotti; Anna Gambini; Enza Palma; Simona Papi; Alice Biroli; Stefania Zaccarelli; Guido Ficarra; Giovanni Tazzioli Journal: Breast Cancer (Auckl) Date: 2021-05-10
Authors: Tatiana Brambilla; Barbara Fiamengo; Corrado Tinterri; Alberto Testori; Massimo Maria Grassi; Amedeo Sciarra; Tommaso Abbate; Wolfgang Gatzemeier; Massimo Roncalli; Luca Di Tommaso Journal: Front Med (Lausanne) Date: 2015-06-04
Authors: Miguel Alonso Ruano; Eugeni Lopez-Bonet; Maria Buxó; Francesc Tuca-Rodríguez; Ester Vila-Camps; Elena Alvarez; Begoña Martin-Castillo; Javier A Menendez Journal: Sci Rep Date: 2014-07-18 Impact factor: 4.379